Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ADR ARGX

Healthcare Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an... see more

Recent & Breaking News (NDAQ:ARGX)

5 Stocks To Watch For March 26, 2018

Benzinga.com  March 26, 2018

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

GlobeNewswire March 26, 2018

argenx reports fourth quarter business update and full year 2017 financial results

GlobeNewswire March 1, 2018

7 Big Companies That Could Tap The IPO Markets In 2018

Benzinga.com  February 22, 2018

argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million

GlobeNewswire December 18, 2017

Mid-Morning Market Update: Markets Rise; Disney To Buy Fox In $52 Billion Deal

Benzinga.com  December 14, 2017

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

GlobeNewswire December 13, 2017

11 Biotech Stocks Moving From ASH 2017

Benzinga.com  December 11, 2017

argenx announces launch of proposed public offering in the United States

GlobeNewswire December 11, 2017

Mid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike Higher

Benzinga.com  December 11, 2017

Mid-Morning Market Update: Markets Edge Higher; 3M To Sell Communication Markets Division For $900M

Benzinga.com  December 11, 2017

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2017

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

GlobeNewswire December 11, 2017

argenx to Present at Upcoming Investor Conferences

GlobeNewswire November 13, 2017

argenx announces results of extraordinary shareholders' meeting 2017

GlobeNewswire November 7, 2017

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

GlobeNewswire November 2, 2017

argenx reports third quarter 2017 financial results and provides business update

GlobeNewswire October 26, 2017

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

GlobeNewswire September 26, 2017

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

GlobeNewswire September 25, 2017

Invitation to the extraordinary shareholders' meeting

GlobeNewswire September 22, 2017